医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Apira Science Warns Chinese Consumers About Unauthorized Online Sales of the iGrow Hair Growth System

2017年01月12日 AM11:00
このエントリーをはてなブックマークに追加


 

BOCA RATON, Fla.

Apira Science, Inc. is warning Chinese consumers to immediately avoid purchasing the iGrow Hair Growth System (the “iGrow”) units that have been listed by unauthorized third-party distributors on Taobao, the online Chinese marketplace founded by the Alibaba Group, and other e-commerce websites.

The iGrow is the safe and effective hands-free low-level light therapy (LLLT) hair growth device designed to treat genetic hair loss. The iGrow was cleared by the China Food and Drug Administration (the “CFDA”) on December 3, 2015, and is legally distributed in China exclusively by China Central Pharmaceuticals.

Only genuine iGrow devices sold through Apira Science’s authorized distributors are protected by Apira Science’s one-year factory warranty. iGrow devices that have been listed on Taobao are not licensed for distribution or sale in China.

Consumers can determine if the iGrow unit they own is properly licensed for purchase and covered by Apira Science’s warranty by examining the device and its packaging. On non-approved units, the handheld remote has five (5) buttons for programmed treatments, while the authorized, CFDA-cleared devices have three (3) buttons. Cleared, approved devices come in a gray sleeve, while non-CFDA-approved units are packed in a red sleeve.

Apira Science advises Chinese consumers to avoid purchasing any iGrow from listings on Taobao or other websites. Apira Science encourages customers who suspect they have purchased the iGrow from an unauthorized distributor to contact Apira Science to verify whether the device is authorized and/or to attempt to return the product to the unauthorized third-party distributor for a refund.

Apira Science is currently working to prevent misuse and stop unauthorized sales and distribution of the iGrow.

About Apira Science, Inc.

Apira Science, Inc. has pioneered low-level light therapy (LLLT) for over a decade. Its iGrow Hair Growth System draws on its expertise and innovations in the application of LLLT to deliver a simple, safe, and effective hair growth treatment. For more information, visit www.igrowlaser.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170111005519/en/

CONTACT

For Apira Science
Gregory
FCA

Denise DiMeglio
610-228-2102
denise@gregoryfca.com
or
For
China Central Pharmaceuticals
Yebin Li
18627017090 (cell)
027-84656086
(office)

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing